MDXG
Price
$3.95
Change
+$0.02 (+0.51%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
588.34M
30 days until earnings call
Intraday BUY SELL Signals
NTLA
Price
$17.57
Change
+$0.33 (+1.91%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
2.45B
25 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MDXG vs NTLA

MDXG vs NTLA Comparison Chart in %
View a ticker or compare two or three
VS
MDXG vs. NTLA commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDXG is a Hold and NTLA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2026
Stock price -- (MDXG: $3.93 vs. NTLA: $16.68)
Brand notoriety: MDXG and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDXG: 278% vs. NTLA: 129%
Market capitalization -- MDXG: $588.34M vs. NTLA: $2.45B
MDXG [@Biotechnology] is valued at $588.34M. NTLA’s [@Biotechnology] market capitalization is $2.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDXG’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • MDXG’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than MDXG.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDXG’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • MDXG’s TA Score: 6 bullish, 3 bearish.
  • NTLA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both MDXG and NTLA are a good buy in the short-term.

Price Growth

MDXG (@Biotechnology) experienced а +3.15% price change this week, while NTLA (@Biotechnology) price change was +4.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

Reported Earning Dates

MDXG is expected to report earnings on Aug 04, 2026.

NTLA is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($2.45B) has a higher market cap than MDXG($588M). NTLA YTD gains are higher at: 85.540 vs. MDXG (-41.950). MDXG has higher annual earnings (EBITDA): 53.2M vs. NTLA (-405.09M). NTLA has more cash in the bank: 376M vs. MDXG (160M). MDXG has less debt than NTLA: MDXG (17.6M) vs NTLA (80.5M). MDXG has higher revenues than NTLA: MDXG (389M) vs NTLA (66.1M).
MDXGNTLAMDXG / NTLA
Capitalization588M2.45B24%
EBITDA53.2M-405.09M-13%
Gain YTD-41.95085.540-49%
P/E Ratio18.35N/A-
Revenue389M66.1M589%
Total Cash160M376M43%
Total Debt17.6M80.5M22%
FUNDAMENTALS RATINGS
MDXG vs NTLA: Fundamental Ratings
MDXG
NTLA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
6199
PRICE GROWTH RATING
1..100
6137
P/E GROWTH RATING
1..100
68100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for MDXG (72). This means that NTLA’s stock grew somewhat faster than MDXG’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MDXG (100). This means that NTLA’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's SMR Rating (61) in the Biotechnology industry is somewhat better than the same rating for NTLA (99). This means that MDXG’s stock grew somewhat faster than NTLA’s over the last 12 months.

NTLA's Price Growth Rating (37) in the Biotechnology industry is in the same range as MDXG (61). This means that NTLA’s stock grew similarly to MDXG’s over the last 12 months.

MDXG's P/E Growth Rating (68) in the Biotechnology industry is in the same range as NTLA (100). This means that MDXG’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDXGNTLA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
86%
Momentum
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
69%
Bullish Trend 4 days ago
79%
Advances
ODDS (%)
Bullish Trend 12 days ago
73%
Bullish Trend 10 days ago
77%
Declines
ODDS (%)
Bearish Trend 28 days ago
81%
Bearish Trend 26 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
86%
Aroon
ODDS (%)
Bullish Trend 4 days ago
63%
Bullish Trend 4 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
MDXG
Daily Signal:
Gain/Loss:
NTLA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PFFV22.020.03
+0.16%
Global X Variable Rate Preferred ETF
CARZ112.29N/A
N/A
First Trust S-Network Fut Vhcl&Tech ETF
UBND21.80N/A
N/A
VictoryShares Core Plus Bond ETF
EMPB32.68-0.31
-0.95%
Efficient Market Portfolio Plus ETF
EPSV30.71-0.73
-2.33%
Harbor Smid Cap Value ETF

MDXG and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDXG has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MDXG jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDXG
1D Price
Change %
MDXG100%
N/A
AXON - MDXG
47%
Loosely correlated
N/A
VCYT - MDXG
42%
Loosely correlated
N/A
ARRY - MDXG
39%
Loosely correlated
N/A
INM - MDXG
38%
Loosely correlated
N/A
TAOX - MDXG
34%
Loosely correlated
N/A
More